Pharma & Biotech Insights, Interviews & Features
Pharmaceutical
21 November 2024 21 November 2024
Today's issue
Refine Search
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
Belgium’s largest drugmaker, UCB, yesterday announced a succession plan for its chief excecutive, Roch Doliveux, saying that Jean-Christophe Tellier, currently executive vice president, Biopharma Brands and Solutions, will be appointed chief executive-elect and chairman of the executive committee as of March 1, 2014. 21 February 2014
Biosimilars
Germany’s Merck KGaA has appointed Simon Sturge to head the biosimilars unit, effective March 1, succeeding Thierry Hulot, who created the biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of last year. 20 February 2014
Pharmaceutical
UK-based drug development company Avillion LLP has appointed Allison Jeynes-Ellis as chief executive. 18 February 2014
Pharmaceutical
US drug developer Inovio Pharmaceuticals has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. 18 February 2014
Biotechnology
US biotech firm Biogen Idec has announced today that chairman of the board William Young, known as Bill, will retire from the company’s Board of Directors, effective at the company’s 2014 annual meeting of stockholders. 17 February 2014
Pharmaceutical
Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Graham Hetherington, chief financial officer, has decided to step down from the company. 13 February 2014
Biotechnology
Exelixis (NASDAQ: EXEL) have announced the appointment of Jeffrey Hessekiel as executive vice president and general counsel. 13 February 2014
Pharmaceutical
European quotas for immigration could have an effect on the pharmaceutical industry, according to recruitment experts. 11 February 2014
Biotechnology
Australia-based biotech company Alchemia has announced the appointment of Santo Costa as non-executive chairman of the Board of Directors, effective March 1. 11 February 2014
Pharmaceutical
The pharmaceutical market is changing, says Georg Toufar, chief marketing officer of Mundipharma International, in an exclusive article for The Pharma Letter, providing some insight on how to deal with these changes. 11 February 2014
Biotechnology
A global survey of chief executives has revealed the priorities and concerns of pharmaceutical and life sciences CEOs. 7 February 2014
Pharmaceutical
‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal Soriot who commented on the firm’s year-end results at a media briefing in London this morning. 6 February 2014
Biotechnology
A UK-based mobile human monitoring company is making waves in health care as it aims to revolutionize the way clinical trial data is collected. 4 February 2014
Pharmaceutical
The founder of Douglas Pharmaceuticals, Sir Graeme Douglas, has announced his retirement as the company’s managing director, effective February 1. 4 February 2014
Pharmaceutical
Global HIV company Viiv Healthcare has launched its first new treatment option for people with HIV today. 3 February 2014
Generics
US generics major Actavis, which now has its headquarters in Ireland, has announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. 1 February 2014
Pharmaceutical
E. Merck KG, which combines the financial interests of the Merck family and is general partner of Germany’s Merck KGaA (MRK: DE) with an interest of 70%, announced at this year's General Partners' Meeting, the family partners elected their representatives to the Family Board, which is the supervisory body of E. Merck KG. 28 January 2014
Pharmaceutical
Karolinska Development has announced that Christian Tange has accepted the role of Chief Financial Officer. 28 January 2014
Biotechnology
US biotech major Gilead Sciences (Nasdaq: GILD) has announced several promotions within the company's senior management team. 28 January 2014
Pharmaceutical
Knowledge is the lifeblood of the pharmaceutical sector. From raw experimental data to complex chemical formulae, from carefully regulated drug trials to patented IP (intellectual property) – without information the industry couldn’t survive, says Phil Greenwood, director, information management and business outsourcing at information management firm Iron Mountain. 28 January 2014
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze